Teva extends Codexis biocatalyst deal
Teva will continue to use Codexis’ biocatalysis technology for key processing steps in the production of four generic drugs under a revised agreement announced last week.
The firms have worked on the project since January last year with Codexis using its proprietary MolecularBreeding technology to develop custom “super enzymes” to accelerate Teva’s production processes.
While further details of deal, or the drugs being produced, were not disclosed Codexis’ CEO, Alan Shaw, said the: "Expansion of our relationship with Teva from one to four products in under a year demonstrates the value of Codexis technology in today's competitive pharmaceuticals market."
Teva and Codexis’ first research collaboration was signed in late 2004, with the Israeli generics giant licensing exclusive rights to commercialise the process in return for providing research funding.
